Haisco Enters $140 Million Deal for Osteoarthritis Therapy

Haisco Pharmaceutical of Shannan in-licensed China rights to a novel osteoarthritis therapy from San Diego 's Biosplice Therapeutics in a $140 million agreement. Lorecivivint, a potential disease-modifying osteoarthritis drug, is a CLK/DYRK kinase inhibitor that modulates the Wnt pathway. It is currently being tested in a US Phase III trial to treat knee osteoarthritis. Biosplice says it has the potential to be the first novel drug therapy for osteoarthritis in nearly 20 years. Haisco will make $20 million in upfront and near-term milestone payments. More details... Stock Symbol: (SHZ: 002653) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.